Rhodiola Rosea
Adaptogen. Salidroside and rosavin inhibit MAO-A/B and modulate serotonin and dopamine reuptake, reducing mental fatigue and improving stress resilience.
This compound sits in research-grey territory. The caveats below carry more weight than for FDA-approved entries — read them.
Well-studied Scandinavian and Soviet adaptogen. Multiple trials show reduced mental fatigue in conditions of stress and shift work. Effect is reliable and fast-onset (30–60 min single dose, versus weeks for ashwagandha). Not a stimulant — effects are blunted cortisol response, not elevated energy.
Mild MAO inhibitor — theoretical interaction with SSRIs and stimulants. Avoid late-day dosing (can be activating). Standardize to rosavins 3% + salidroside 1%.
Per-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.
- CLimited evidence
Rhodiola Rosea — primary mechanism: adaptogen. salidroside and rosavin inhibit mao-a/b and modulate serotonin and dopamine reuptake, reducing mental fatigue and improving stress resilience.
2 supporting referencesVerified 5d ago
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
Dietary supplement. EMA approved for traditional-use fatigue in EU.